Atypical Hyperplasia of the Breast — Risk Assessment and Management Options

Abstract

The criteria for inclusion in the table were a central pathological review and the use of the criteria of David Page and colleagues for the diagnosis of atypical hyperplasia. 9CI denotes confidence interval.† The study was a retrospective cohort study involving women who had excisional biopsies performed during the period 1950 -1968.The median duration of follow-up was 17 years.Risk estimates are for invasive breast cancer only.‡ The study was a retrospective cohort study involving women who had excisional biopsies, core biopsies, or both performed during the period 1967-2001.The median duration of follow-up was 12.1 years.Risk estimates are for both invasive and in situ breast cancer (19% of cases were in situ).The numbers of patients in subcategories may not add to the total because information was missing for some patients.§ A strong family history was defined as at least one first-degree relative with breast cancer before 50 years of age or two or more relatives with breast cancer, with at least one being a first-degree relative.A weak family history was defined as any lesser degree of family history.¶ The study was a retrospective cohort study involving women who had biopsies performed during the period 1981-1994.The duration of follow-up was not specified.Risk estimates are for both invasive and in situ breast cancer (20% of cases were in situ).‖ The study was a nested case-control study.The type of breast cancer (i.e., invasive or in situ) evaluated for the risk estimates was not specified.** The study was a nested case-control study; risk estimates are for both invasive and in situ breast cancer.